Drugs / Shz QIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03430089 | Feb → Jun 2019 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shz QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03430089 ↗ |
| Modality | Vaccine | “quadrivalent inactivated influenza vaccine” PMID 36328438 ↗ Nov 2022 |
| Route | Intramuscular | “Administered intramuscularly” NCT03430089 ↗ |